Sugar phosphate metabolizing enzyme

Sugar phosphate metabolizing enzymes constitute a broad functional class of enzymes responsible for the interconversion and regulation of phosphorylated sugars within central metabolic pathways, such as glycolysis, the pentose phosphate pathway, and gluconeogenesis (UniProt). This group includes critical therapeutic targets like hexokinase (HK), phosphofructokinase (PFK), and glucose-6-phosphate dehydrogenase (G6PD), which are essential for cellular energy production, redox homeostasis, and the synthesis of metabolic intermediates (PubMed: 29056358). In many diseases, particularly cancer, these enzymes are significantly upregulated to support the high metabolic demands of rapid cell proliferation, a phenomenon known as the Warburg effect (PubMed: 25635394). Consequently, inhibitors of these enzymes, such as PFKFB3 inhibitors (e.g., PFK158) and hexokinase inhibitors (e.g., 2-deoxy-D-glucose), are being investigated as potential anti-cancer agents to disrupt tumor metabolism (PubMed: 28468910). Additionally, mutations in these enzymes are associated with various metabolic disorders, including G6PD deficiency, which can lead to hemolytic anemia under oxidative stress (PubMed: 28213252). Because these enzymes are fundamental to the metabolism of all cells, achieving therapeutic selectivity while minimizing systemic toxicity, such as hypoglycemia or metabolic acidosis, remains a primary challenge in drug development (PubMed: 29056358).

Other names

Sugar phosphate phosphataseSugar phosphate isomeraseSugar phosphate kinaseGlycolytic enzymePentose phosphate pathway enzyme

Inhibition of glycolytic flux, modulation of the pentose phosphate pathway, or activation of metabolic checkpoints to disrupt energy production or biosynthetic precursors in diseased cells.